UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000049606 |
|---|---|
| Receipt number | R000056499 |
| Scientific Title | Post-marketing surveillance: Long term efficacy and safety of Valbenazine in patients with tardive dyskinesia |
| Date of disclosure of the study information | 2022/12/16 |
| Last modified on | 2025/12/01 11:43:07 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Post-marketing surveillance: Long term efficacy and safety of Valbenazine in patients with tardive dyskinesia
Acronym
AKARI
Scientific Title
Post-marketing surveillance: Long term efficacy and safety of Valbenazine in patients with tardive dyskinesia
Scientific Title:Acronym
AKARI
Region
| Japan |
Condition
Condition
Tardive Dyskinesia
Classification by specialty
| Neurology | Psychosomatic Internal Medicine | Psychiatry |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To verify the safety and efficacy of long-term treatment with Dysval capsules in the real-world in patients with tardive dyskinesia
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Not applicable
Assessment
Primary outcomes
Safety
-Adverse reaction profile
-Examination of patient background factors affecting safety
-Clinical global impression - severity of underlying disease (CGI-S)
-Comparison of safety between doses of this drug
Efficacy
-Clinical global impression of improvement of tardive dyskinesia (CGI-TD)
-Examination of patient background factors affecting efficacy
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
-Patients with tardive dyskinesia who receive this drug for the first time
-Patients who give written consent to participate in this surveillance
Key exclusion criteria
-Patients with a history of hypersensitivity to any in-gredients of this drug
-Patients with long QT syndrome congenital or a history of Torsades de pointes [excessive QT interval prolongation, ventricular tachycardia (including Torsades de pointes) may occur.]
Target sample size
500
Research contact person
Name of lead principal investigator
| 1st name | Ikumi |
| Middle name | |
| Last name | Fukuyama |
Organization
Tanabe Pharma Corporation
Division name
Pharmacovigilance Department
Zip code
541-8505
Address
3-2-10, Dosho-machi, Chuo-ku, Osaka 541-8505, Japan
TEL
06-6205-5223
ikumi.fukuyama@tanabe-pharma.com
Public contact
Name of contact person
| 1st name | Kaoru |
| Middle name | |
| Last name | Ishizaki |
Organization
Tanabe Pharma Corporation
Division name
Pharmacovigilance Department
Zip code
100-8205
Address
1-1-1, Marunouchi, Chiyoda-ku, Tokyo 100-8205, Japan
TEL
03-6748-7733
Homepage URL
tp-pms-shinchoku.JP@ml.tanabe-pharma.com
Sponsor or person
Institute
Tanabe Pharma Corporation
Institute
Department
Personal name
Funding Source
Organization
Tanabe Pharma Corporation
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Not applicable
Address
Not applicable
Tel
Not applicable
Not applicable
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2022 | Year | 12 | Month | 16 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2022 | Year | 05 | Month | 20 | Day |
Date of IRB
| 2023 | Year | 01 | Month | 16 | Day |
Anticipated trial start date
| 2023 | Year | 01 | Month | 16 | Day |
Last follow-up date
| 2026 | Year | 01 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Post-Marketing Surveillance
Management information
Registered date
| 2022 | Year | 11 | Month | 25 | Day |
Last modified on
| 2025 | Year | 12 | Month | 01 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000056499
